ArticleAmerican journal of translational research2025
Effect of octreotide combined with ulinastatin on the creatinine-to-albumin ratio and systemic immune-inflammation index in patients with severe acute pancreatitis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and safety of Xuebijing combined with ulinastatin in the treatment of sepsis complicated by acute lung injury: a meta-analysis.American journal of translational research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effects of combined octreotide and ulinastatin therapy on the serum creatinine-to-albumin ratio (CAR) and systemic immune-inflammation index (SII) in patients with severe acute pancreatitis (SAP), and to investigate its impact on inflammatory markers, organ function, and clinical outcomes.
methodsThis single-center, retrospective cohort study included 240 SAP patients admitted to Northwest University Affiliated Xi'an No. 3 Hospital between October 2021 and April 2023. The control group (n=112) received octreotide 0.1 mg subcutaneously every 8 hours, while the observation group (n=128) received ulinastatin 100,000 U intravenously once daily for 7-14 days. Primary outcomes included 28-day mortality, Intensive care unit (ICU) stay, hospital stay, and 1-year recurrence. Secondary outcomes included CAR, SII, creatinine (Cr), serum amylase, albumin (Alb), C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6), measured on days 1, 3, 7, and 14. Complications and adverse events were recorded based on standardized criteria.
resultsFrom days 1 to 14, the observation group exhibited larger reductions in CAR and SII, lower Cr, CRP, PCT, and IL-6, and higher Alb (all P<0.05). Combined therapy reduced the 28-day mortality (P=0.038), 1-year recurrence (P=0.016), and the overall complication rate (P=0.003). Day-14 CAR and SII effectively predicted 28-day mortality and 1-year recurrence with an area under the curve greater than 0.7.
conclusionsThe addition of ulinastatin to octreotide therapy in SAP significantly reduces inflammation and organ injury, improving short-term survival and decreasing mid-term recurrence. CAR and SII are promising prognostic biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.